StockData
Kyntra Bio, Inc. logo

Kyntra Bio, Inc. (KYNB) stock

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.95−0.09 (-4.41%)

Close on Nov 18, 2026Market cap $7.90MP/E 0.0Yield –

Kyntra Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kyntra Bio's operating income for the twelve months ending Jun 30, 2026 was -$50.32M. For fiscal 2025 it was -$45.90M. The highest annual figure on record is -$7.95M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.90M–
FY2024Dec 31, 2024-$150.42M–
FY2023Dec 31, 2023-$322.72M–
FY2022Dec 31, 2022-$301.03M–
FY2021Dec 31, 2021-$288.53M–
FY2020Dec 31, 2020-$191.88M–
FY2019Dec 31, 2019-$89.31M–
FY2018Dec 31, 2018-$86.69M–
FY2017Dec 31, 2017-$117.28M–
FY2016Dec 31, 2016-$50.04M–
FY2015Dec 31, 2015-$77.63M–
FY2014Dec 31, 2014-$50.10M–
FY2013Dec 31, 2013-$7.95M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.57M–
Q1 FY2026Mar 31, 2026-$13.82M–
Q4 FY2025Dec 31, 2025-$13.51M–
Q3 FY2025Sep 30, 2025-$5.41M–
Q2 FY2025Jun 30, 2025-$12.05M–
Q1 FY2025Mar 31, 2025-$14.92M–
Q4 FY2024Dec 31, 2024-$7.13M–
Q3 FY2024Sep 30, 2024-$47.69M–
Q2 FY2024Jun 30, 2024-$46.41M–
Q1 FY2024Mar 31, 2024-$49.18M–
Q4 FY2023Dec 31, 2023-$95.10M–
Q3 FY2023Sep 30, 2023-$63.48M–
Q2 FY2023Jun 30, 2023-$88.05M–
Q1 FY2023Mar 31, 2023-$76.09M–
Q4 FY2022Dec 31, 2022-$66.15M–
Q3 FY2022Sep 30, 2022-$93.66M-283.7%
Q2 FY2022Jun 30, 2022-$78.22M–
Q1 FY2022Mar 31, 2022-$62.99M–
Q4 FY2021Dec 31, 2021-$135.24M–
Q3 FY2021Sep 30, 2021$50.97M+57.7%
Q2 FY2021Jun 30, 2021-$133.84M–
Q1 FY2021Mar 31, 2021-$70.43M–
Q4 FY2020Dec 31, 2020-$58.00M–
Q3 FY2020Sep 30, 2020$32.33M–
Q2 FY2020Jun 30, 2020-$85.14M-175.5%
Q1 FY2020Mar 31, 2020-$81.07M–
Q4 FY2019Dec 31, 2019-$100.44M-604.2%
Q3 FY2019Sep 30, 2019-$52.85M–
Q2 FY2019Jun 30, 2019$112.82M–
Q1 FY2019Mar 31, 2019-$48.84M–
Q4 FY2018Dec 31, 2018$19.92M–
Q3 FY2018Sep 30, 2018-$42.77M–
Q2 FY2018Jun 30, 2018-$23.24M–
Q1 FY2018Mar 31, 2018-$40.60M–
Q4 FY2017Dec 31, 2017-$35.58M–
Q3 FY2017Sep 30, 2017-$22.74M–
Q2 FY2017Jun 30, 2017-$30.14M–
Q1 FY2017Mar 31, 2017-$28.82M–
Q4 FY2016Dec 31, 2016-$27.67M–
Q3 FY2016Sep 30, 2016-$22.10M–

More Kyntra Bio figures

See a number that looks wrong?